Skip to main content
. 2022 Sep 6;92(4):470–478. doi: 10.1134/S1019331622040256

Fig. 2.

Fig. 2.

Structure of some nucleoside RDRP inhibitors: (a) sofosbuvir, (b) favipiravir, (c) ribavirin, (d) remdesivir, and (e) molnupiravir.